Fate Therapeutics Q4 2021 revenue $17.1M, cash $716.6M; FT596 data shows 69% ORR, FT516 gets RMAT

FATE THERAPEUTICS INC

2022-FY EPS reported -$2.24 revenue$55,846,000

Q4 2021 revenue $17.1M from collaborations; R&D expenses $69.5M (incl. $9.4M stock comp).
Cash position $716.6M at Dec 31, 2021; FY2022 GAAP loss from ops guided $335-365M; cash use $290-315M; year-end cash >$400M.
FT596+R single-dose cohorts (≥90M cells, n=16): 69% ORR, 56% CR; no ICANS or GVHD.
FDA granted RMAT designation for FT516 in r/r DLBCL; expansion cohorts enrolling at 900M cells/dose.
Initial FT819 dose cohort cleared with no DLTs; Janssen collaboration triggered milestone for second CAR NK candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.